{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T04:33:10Z","timestamp":1790137990086,"version":"4.0.1"},"reference-count":112,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,7,15]],"date-time":"2019-07-15T00:00:00Z","timestamp":1563148800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003180","name":"Academisch Medisch Centrum","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003180","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Virology"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.coviro.2019.07.007","type":"journal-article","created":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T22:54:09Z","timestamp":1565823249000},"page":"70-80","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"special_numbering":"C","title":["The potential of engineered antibodies for HIV-1 therapy and cure"],"prefix":"10.1016","volume":"38","author":[{"given":"Marloes","family":"Grobben","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard AL","family":"Stuart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marit J","family":"van Gils","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coviro.2019.07.007_bib0005","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S0140-6736(14)60164-1","article-title":"HIV infection: epidemiology, pathogenesis, treatment, and prevention","volume":"384","author":"Maartens","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.coviro.2019.07.007_bib0010","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1371\/journal.ppat.0030046","article-title":"ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia","volume":"3","author":"Maldarelli","year":"2007","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2019.07.007_bib0015","doi-asserted-by":"crossref","first-page":"e81355","DOI":"10.1371\/journal.pone.0081355","article-title":"Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada","volume":"30","author":"Samji","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.coviro.2019.07.007_bib0020","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/S0140-6736(13)61809-7","article-title":"The end of AIDS: HIV infection as a chronic disease","volume":"382","author":"Deeks","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.coviro.2019.07.007_bib0025","first-page":"343","article-title":"The size of the active HIV reservoir predicts timing of viral rebound [abstract 110 LB]","volume":"30","author":"Li","year":"2016","journal-title":"AIDS"},{"key":"10.1016\/j.coviro.2019.07.007_bib0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.ppat.1005535","article-title":"Real-time predictions of reservoir size and rebound time during antiretroviral therapy interruption trials for HIV","volume":"12","author":"Hill","year":"2016","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2019.07.007_bib0035","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1126\/science.aaf0972","article-title":"HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1","volume":"352","author":"Schoofs","year":"2016","journal-title":"Science (80-)"},{"key":"10.1016\/j.coviro.2019.07.007_bib0040","doi-asserted-by":"crossref","first-page":"9523","DOI":"10.1073\/pnas.1120248109","article-title":"Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection","volume":"109","author":"Archin","year":"2012","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.coviro.2019.07.007_bib0045","doi-asserted-by":"crossref","first-page":"e1005535","DOI":"10.1038\/72318","article-title":"Protection of macaques against vaginal transmission of a pathogenic HIV- 1\/SIV chimeric virus by passive infusion of neutralizing antibodies","volume":"6","author":"Mascola","year":"2000","journal-title":"Nat Med"},{"key":"10.1016\/j.coviro.2019.07.007_bib0050","doi-asserted-by":"crossref","first-page":"e1000433","DOI":"10.1371\/journal.ppat.1000433","article-title":"Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers","volume":"5","author":"Hessell","year":"2009","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2019.07.007_bib0055","doi-asserted-by":"crossref","first-page":"18921","DOI":"10.1073\/pnas.1214785109","article-title":"Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo","volume":"109","author":"Moldt","year":"2012","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.coviro.2019.07.007_bib0060","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nature17677","article-title":"A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges","volume":"533","author":"Gautam","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2019.07.007_bib0065","first-page":"1001","article-title":"Enhanced clearance of HIV-1-infected cells by anti-HIV-1 broadly neutralizing antibodies in vivo","volume":"352","author":"Lu","year":"2016","journal-title":"HHS Public Access"},{"key":"10.1016\/j.coviro.2019.07.007_bib0070","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.cell.2014.08.023","article-title":"Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity","volume":"158","author":"Bournazos","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.coviro.2019.07.007_bib0075","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/imr.12339","article-title":"The role of Fc receptors in HIV prevention and therapy","volume":"268","author":"Boesch","year":"2015","journal-title":"Immunol Rev"},{"key":"10.1016\/j.coviro.2019.07.007_sbref0080","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/s41586-018-0531-2","article-title":"Combination therapy with anti-HIV-1 antibodies maintains viral suppression","volume":"561","author":"Mendoza","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2019.07.007_bib0085","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nature14411","article-title":"Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117","volume":"522","author":"Caskey","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2019.07.007_bib0090","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad5752","article-title":"Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection","volume":"7","author":"Lynch","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coviro.2019.07.007_bib0095","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1056\/NEJMoa1608243","article-title":"Effect of HIV antibody VRC01 on viral rebound after treatment interruption","volume":"375","author":"Bar","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2019.07.007_bib0100","doi-asserted-by":"crossref","first-page":"4201","DOI":"10.1128\/JVI.03608-14","article-title":"HIV-1 fitness cost associated with escape from the VRC01 class of CD4 binding site neutralizing antibodies","volume":"89","author":"Lynch","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2019.07.007_bib0105","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1126\/science.8493564","article-title":"AIDS research: the mood is uncertain","volume":"260","author":"Cohen","year":"2006","journal-title":"Science (80-)"},{"key":"10.1016\/j.coviro.2019.07.007_sbref0110","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/s41591-018-0186-4","article-title":"Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals","volume":"24","author":"Bar-On","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.coviro.2019.07.007_bib0115","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nature11604","article-title":"HIV therapy by a combination of broadly neutralizing antibodies in humanized mice","volume":"492","author":"Klein","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2019.07.007_bib0120","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/nature12744","article-title":"Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys","volume":"503","author":"Barouch","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2019.07.007_sbref0125","doi-asserted-by":"crossref","first-page":"e1002435","DOI":"10.1371\/journal.pmed.1002435","article-title":"Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: results of a phase 1 randomized trial","volume":"14","author":"Mayer","year":"2017","journal-title":"PLoS Med"},{"key":"10.1016\/j.coviro.2019.07.007_bib0130","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nri2206","article-title":"Fc\u03b3 receptors as regulators of immune responses","volume":"8","author":"Nimmerjahn","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.coviro.2019.07.007_bib0135","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1084\/jem.20151267","article-title":"The role of Fc\u2013Fc\u03b3R interactions in IgG-mediated microbial neutralization","volume":"212","author":"Bournazos","year":"2015","journal-title":"J Exp Med"},{"key":"10.1016\/j.coviro.2019.07.007_bib0140","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature06106","article-title":"Fc receptor but not complement binding is important in antibody protection against HIV","volume":"449","author":"Hessell","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2019.07.007_bib0145","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/nm.1974","article-title":"Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques","volume":"15","author":"Hessell","year":"2009","journal-title":"Nat Med"},{"key":"10.1016\/j.coviro.2019.07.007_bib0150","doi-asserted-by":"crossref","first-page":"e1006987","DOI":"10.1371\/journal.ppat.1006987","article-title":"HIV-specific Fc effector function early in infection predicts the development of broadly neutralizing antibodies","volume":"14","author":"Richardson","year":"2018","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2019.07.007_bib0155","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jim.2012.07.006","article-title":"Role of monocytes in mediating HIV-specific antibody-dependent cellular cytotoxicity","volume":"384","author":"Kramski","year":"2012","journal-title":"J Immunol Method"},{"key":"10.1016\/j.coviro.2019.07.007_bib0160","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jim.2018.09.009","article-title":"Measuring the ability of HIV-specific antibodies to mediate trogocytosis","volume":"463","author":"Richardson","year":"2018","journal-title":"J Immunol Method"},{"key":"10.1016\/j.coviro.2019.07.007_bib0165","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.4049\/jimmunol.157.5.2168","article-title":"HIV-1 gp120-specific antibody-dependent cell-mediated cytotoxicity correlates with rate of disease progression","volume":"157","author":"Baum","year":"1996","journal-title":"J Immunol"},{"key":"10.1016\/j.coviro.2019.07.007_bib0170","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1023\/A:1011087132180","article-title":"Evidence for a correlation between antibody-dependent cellular cytotoxicity-mediating anti-HIV-1 antibodies and prognostic predictors of HIV infection","volume":"21","author":"Ahmad","year":"2001","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.coviro.2019.07.007_bib0175","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/QAI.0b013e31822c62b9","article-title":"Activation of NK cells by ADCC antibodies and HIV disease progression","volume":"58","author":"Chung","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.coviro.2019.07.007_bib0180","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/imm.12016","article-title":"Specific antibody-dependent cellular cytotoxicity responses associated with slow progression of HIV infection","volume":"138","author":"Wren","year":"2013","journal-title":"Immunology"},{"key":"10.1016\/j.coviro.2019.07.007_bib0185","doi-asserted-by":"crossref","first-page":"e74855","DOI":"10.1371\/journal.pone.0074855","article-title":"High antibody-dependent cellular cytotoxicity responses are correlated with strong CD8 T cell viral suppressive activity but not with B57 status in HIV-1 elite controllers","volume":"8","author":"Lambotte","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.coviro.2019.07.007_bib0190","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.4049\/jimmunol.174.4.2185","article-title":"Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute Viremia in Rhesus macaques challenged with SIVmac251","volume":"174","author":"Gomez-Roman","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.coviro.2019.07.007_bib0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.ppat.1005090","article-title":"AAV-delivered antibody mediates significant protective effects against SIVmac239 challenge in the absence of neutralizing activity","volume":"11","author":"Fuchs","year":"2015","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2019.07.007_bib0200","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/mi.2013.23","article-title":"Protective effect of vaginal application of neutralizing and nonneutralizing inhibitory antibodies against vaginal SHIV challenge in macaques","volume":"7","author":"Moog","year":"2014","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.coviro.2019.07.007_bib0205","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1056\/NEJMoa1113425","article-title":"Immune-correlates analysis of an HIV-1 vaccine efficacy trial","volume":"366","author":"Haynes","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2019.07.007_bib0210","doi-asserted-by":"crossref","first-page":"11521","DOI":"10.1128\/JVI.01023-12","article-title":"Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family","volume":"86","author":"Bonsignori","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2019.07.007_bib0215","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.03403-12","article-title":"Enhanced phagocytic activity of HIV-specific antibodies correlates with natural production of immunoglobulins with skewed affinity for Fc R2a and Fc R2b","author":"Ackerman","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2019.07.007_bib0220","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.virol.2011.03.012","article-title":"Decreased Fc receptor expression on innate immune cells is associated with impaired antibody-mediated cellular phagocytic activity in chronically HIV-1 infected individuals","volume":"415","author":"Dugast","year":"2011","journal-title":"Virology"},{"key":"10.1016\/j.coviro.2019.07.007_bib0225","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.cell.2013.09.061","article-title":"Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys","volume":"155","author":"Barouch","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.coviro.2019.07.007_bib0230","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1126\/science.aab3886","article-title":"Protective efficacy of adenovirus\/protein vaccines against SIV challenges in rhesus monkeys","volume":"349","author":"Barouch","year":"2015","journal-title":"Science (80-)"},{"key":"10.1016\/j.coviro.2019.07.007_bib0235","doi-asserted-by":"crossref","first-page":"e441","DOI":"10.1371\/journal.pmed.0030441","article-title":"Complement lysis activity in autologous plasma is associated with lower viral loads during the acute phase of HIV-1 infection","volume":"3","author":"Huber","year":"2006","journal-title":"PLoS Med"},{"key":"10.1016\/j.coviro.2019.07.007_bib0240","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1128\/JVI.79.5.2823-2830.2005","article-title":"Detection of antibody-dependent complement-mediated inactivation of both autologous and heterologous virus in primary human immunodeficiency virus type 1 infection","volume":"79","author":"Aasa-Chapman","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2019.07.007_bib0245","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aat7796","article-title":"Antigen-specific antibody Fc glycosylation enhances humoral immunity via the recruitment of complement","volume":"3","author":"Lofano","year":"2018","journal-title":"Sci Immunol"},{"key":"10.1016\/j.coviro.2019.07.007_bib0250","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/intimm\/dxs048","article-title":"High reproducible ADCC analysis revealed a competitive relation between ADCC and CDC and differences between Fc\u03b3rllla polymorphism","volume":"24","author":"Mishima","year":"2012","journal-title":"Int Immunol"},{"key":"10.1016\/j.coviro.2019.07.007_bib0255","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1182\/blood-2007-02-074716","article-title":"NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement","volume":"111","author":"Wang","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.coviro.2019.07.007_bib0260","doi-asserted-by":"crossref","first-page":"5322","DOI":"10.1182\/blood-2009-01-200469","article-title":"Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model","volume":"114","author":"Wang","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.coviro.2019.07.007_bib0265","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.4049\/jimmunol.1500618","article-title":"Impaired NK Cell Activation and Chemotaxis toward Dendritic Cells Exposed to Complement-Opsonized HIV-1","volume":"195","author":"Elleg\u00e5rd","year":"2015","journal-title":"J Immunol"},{"key":"10.1016\/j.coviro.2019.07.007_sbref0270","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s13238-017-0473-8","article-title":"IgG Fc engineering to modulate antibody effector functions","volume":"9","author":"Wang","year":"2018","journal-title":"Protein Cell"},{"key":"10.1016\/j.coviro.2019.07.007_bib0275","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/0161-5890(90)90103-7","article-title":"A protein structural change in aglycosylated IgG3 correlates with loss of huFc\u03b3R1 and hufc\u03b3R111 binding and\/or activation","volume":"27","author":"Lund","year":"1990","journal-title":"Mol Immunol"},{"key":"10.1016\/j.coviro.2019.07.007_bib0280","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1097\/QAD.0000000000000444","article-title":"Identification of antibody glycosylation structures that predict monoclonal antibody Fc-effector function","volume":"28","author":"Chung","year":"2014","journal-title":"AIDS"},{"key":"10.1016\/j.coviro.2019.07.007_bib0285","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1158\/1078-0432.CCR-12-0989","article-title":"GA201 (RG7160): a novel, humanized, glycoengineered anti - EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab","volume":"19","author":"Gerdes","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.coviro.2019.07.007_bib0290","doi-asserted-by":"crossref","first-page":"e0134949","DOI":"10.1371\/journal.pone.0134949","article-title":"In vitro glycoengineering of IgG1 and its effect on Fc receptor binding and ADCC activity","volume":"10","author":"Thomann","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.coviro.2019.07.007_bib0295","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/bit.1119","article-title":"Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for Fc\u03b3RIII","volume":"74","author":"Davies","year":"2001","journal-title":"Biotechnol Bioeng"},{"key":"10.1016\/j.coviro.2019.07.007_sbref0300","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1080\/19420862.2018.1551044","article-title":"Influence of N-glycosylation on effector functions and thermal stability of glycoengineered IgG1 monoclonal antibody with homogeneous glycoforms","volume":"11","author":"Wada","year":"2019","journal-title":"MAbs"},{"key":"10.1016\/j.coviro.2019.07.007_bib0305","doi-asserted-by":"crossref","first-page":"26733","DOI":"10.1074\/jbc.M202069200","article-title":"Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fc\u03b3RIII and antibody-dependent cellular toxicity","volume":"277","author":"Shields","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coviro.2019.07.007_bib0310","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1074\/jbc.M210665200","article-title":"The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity","volume":"278","author":"Shinkawa","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coviro.2019.07.007_bib0315","doi-asserted-by":"crossref","first-page":"419","DOI":"10.4161\/mabs.20996","article-title":"Marketing approval of mogamulizumab: a triumph for glyco-engineering","volume":"4","author":"Beck","year":"2012","journal-title":"MAbs"},{"key":"10.1016\/j.coviro.2019.07.007_bib0320","doi-asserted-by":"crossref","first-page":"36964","DOI":"10.1038\/srep36964","article-title":"Multi-level glyco-engineering techniques to generate IgG with defined Fc-glycans","volume":"6","author":"Dekkers","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.coviro.2019.07.007_bib0325","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.3389\/fimmu.2017.01860","article-title":"Engineering of Fc fragments with optimized physicochemical properties implying improvement of clinical potentials for Fc-based therapeutics","volume":"8","author":"Yang","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.coviro.2019.07.007_sbref0330","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/s41591-018-0001-2","article-title":"A single injection of crystallizable fragment domain-modified antibodies elicits durable protection from SHIV infection","volume":"24","author":"Gautam","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.coviro.2019.07.007_bib0335","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nature13612","article-title":"Enhanced neonatal Fc receptor function improves protection against primate SHIV infection","volume":"514","author":"Ko","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2019.07.007_sbref0340","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002493","article-title":"Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: a Phase 1 open-label clinical trial in healthy adults","volume":"15","author":"Gaudinski","year":"2018","journal-title":"PLOS Med"},{"key":"10.1016\/j.coviro.2019.07.007_bib0345","doi-asserted-by":"crossref","first-page":"23514","DOI":"10.1074\/jbc.M604292200","article-title":"Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn)","volume":"281","author":"Dall\u2019Acqua","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coviro.2019.07.007_bib0350","doi-asserted-by":"crossref","first-page":"6147","DOI":"10.1128\/AAC.01285-13","article-title":"A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults","volume":"57","author":"Robbie","year":"2013","journal-title":"Antimicrob Agent Chemother"},{"key":"10.1016\/j.coviro.2019.07.007_bib0355","doi-asserted-by":"crossref","first-page":"332","DOI":"10.4161\/mabs.1.4.9122","article-title":"Human immunoglobulin allotypes: possible implications for immunogenicity","volume":"1","author":"Jefferis","year":"2009","journal-title":"MAbs"},{"key":"10.1016\/j.coviro.2019.07.007_bib0360","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2014.00520","article-title":"IgG subclasses and allotypes: from structure to effector functions","volume":"5","author":"Vidarsson","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.coviro.2019.07.007_bib0365","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1097\/QAD.0000000000001716","article-title":"Temporal variation in HIV-specific IgG subclass antibodies during acute infection differentiates spontaneous controllers from chronic progressors","volume":"32","author":"Sadanand","year":"2018","journal-title":"AIDS"},{"key":"10.1016\/j.coviro.2019.07.007_bib0370","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/j.cell.2016.04.050","article-title":"Bispecific anti-HIV-1 antibodies with enhanced breadth and potency","volume":"165","author":"Bournazos","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.coviro.2019.07.007_bib0375","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms1608","article-title":"Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential","volume":"2","author":"Stapleton","year":"2011","journal-title":"Nat Commun"},{"key":"10.1016\/j.coviro.2019.07.007_bib0380","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1084\/jem.20130221","article-title":"Restricting HIV-1 pathways for escape using rationally designed anti\u2013HIV-1 antibodies","volume":"210","author":"Diskin","year":"2013","journal-title":"J Exp Med"},{"key":"10.1016\/j.coviro.2019.07.007_bib0385","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nri2747","article-title":"Strategies and challenges for the next generation of therapeutic antibodies","volume":"10","author":"Beck","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.coviro.2019.07.007_bib0390","doi-asserted-by":"crossref","first-page":"12501","DOI":"10.1128\/JVI.02097-15","article-title":"Bispecific antibodies targeting different epitopes on the HIV-1 envelope exhibit broad and potent neutralization","volume":"89","author":"Asokan","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2019.07.007_sbref0395","doi-asserted-by":"crossref","first-page":"e1006860","DOI":"10.1371\/journal.ppat.1006860","article-title":"Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections","volume":"14","author":"Wagh","year":"2018","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2019.07.007_bib0400","doi-asserted-by":"crossref","first-page":"e1005233","DOI":"10.1371\/journal.ppat.1005233","article-title":"Targeting HIV reservoir in infected CD4 T cells by dual-affinity re-targeting molecules (DARTs) that bind HIV envelope and recruit cytotoxic T cells","volume":"11","author":"Sloan","year":"2015","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2019.07.007_bib0405","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1016\/j.cell.2016.05.024","article-title":"engineered bispecific antibodies with exquisite HIV-1-neutralizing activity","volume":"165","author":"Huang","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.coviro.2019.07.007_bib0410","doi-asserted-by":"crossref","first-page":"13540","DOI":"10.1073\/pnas.1304985110","article-title":"Bispecific antibodies directed to CD4 domain 2 and HIV envelope exhibit exceptional breadth and picomolar potency against HIV-1","volume":"110","author":"Pace","year":"2013","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.coviro.2019.07.007_sbref0415","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/s41467-018-03335-4","article-title":"Rational design of a trispecific antibody targeting the HIV-1 Env with elevated anti-viral activity","volume":"9","author":"Steinhardt","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.coviro.2019.07.007_bib0420","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ymeth.2018.10.010","article-title":"Bispecific antibodies: Potential immunotherapies for HIV treatment","volume":"154","author":"Fabozzi","year":"2018","journal-title":"Methods"},{"key":"10.1016\/j.coviro.2019.07.007_bib0425","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s00262-005-0001-1","article-title":"T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19\/anti-CD3 single-chain antibody construct","volume":"55","author":"Schlereth","year":"2006","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.coviro.2019.07.007_bib0430","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms9447","article-title":"Activation and lysis of human CD4 cells latently infected with HIV-1","volume":"6","author":"Pegu","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.coviro.2019.07.007_bib0435","doi-asserted-by":"crossref","first-page":"4077","DOI":"10.1172\/JCI82314","article-title":"Dual-affinity re-targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells","volume":"125","author":"Sung","year":"2015","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coviro.2019.07.007_bib0440","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/FPC.0b013e32832a06bf","article-title":"IgG1 heavy chain-coding gene polymorphism (G1m allotypes) and development of antibodies-to-infliximab","volume":"19","author":"Magdelaine-Beuzelin","year":"2009","journal-title":"Pharmacogenet Genomic"},{"key":"10.1016\/j.coviro.2019.07.007_bib0445","doi-asserted-by":"crossref","first-page":"R221","DOI":"10.1186\/ar3208","article-title":"Surprising negative association between IgG1 allotype disparity and anti-adalimumab formation: a cohort study","volume":"12","author":"Bartelds","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.coviro.2019.07.007_bib0450","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1146\/annurev-med-061016-041032","article-title":"New-generation high-potency and designer antibodies: role in HIV-1 treatment","volume":"69","author":"Gama","year":"2018","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.coviro.2019.07.007_sbref0455","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1126\/science.aan8630","article-title":"Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques","volume":"358","author":"Xu","year":"2017","journal-title":"Science (80-)"},{"key":"10.1016\/j.coviro.2019.07.007_bib0460","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1365-2249.2009.03980.x","article-title":"Functional and clinical consequences of Fc receptor polymorphic and copy number variants","volume":"157","author":"Bournazos","year":"2009","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.coviro.2019.07.007_bib0465","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12977-016-0272-y","article-title":"Perinatal HIV-1 transmission: Fc gamma receptor variability associates with maternal infectiousness and infant susceptibility","volume":"13","author":"Lassauni\u00e8re","year":"2016","journal-title":"Retrovirology"},{"key":"10.1016\/j.coviro.2019.07.007_bib0470","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S0140-6736(88)91657-1","article-title":"Antibody-dependent enhancement of human immunodeficiency virus Type 1 infection","volume":"331","author":"Robinson","year":"1988","journal-title":"Lancet"},{"key":"10.1016\/j.coviro.2019.07.007_bib0475","first-page":"33","article-title":"Complement-mediated, antibody-dependent enhancement of HIV-1 infection in vitro is characterized by increased protein and RNA syntheses and infectious virus release","volume":"2","author":"Robinson","year":"1989","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.coviro.2019.07.007_bib0480","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1097\/00002030-199708000-00002","article-title":"Two parallel routes of the complement-mediated antibody-dependent enhancement of HIV-1 infection","volume":"11","author":"Proh\u00e1szka","year":"1997","journal-title":"AIDS"},{"key":"10.1016\/j.coviro.2019.07.007_bib0485","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1365-2249.1994.tb06040.x","article-title":"Antibody-dependent enhancement of HIV-1 infection in human term syncytiotrophoblast cells cultured in vitro","volume":"96","author":"Toth","year":"1994","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.coviro.2019.07.007_bib0490","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pmed.1002183","article-title":"Patient-reported barriers to adherence to antiretroviral therapy: a systematic review and meta-analysis","volume":"13","author":"Shubber","year":"2016","journal-title":"PLoS Med"},{"key":"10.1016\/j.coviro.2019.07.007_bib0495","first-page":"1443","article-title":"Common adverse effects of antiretroviral therapy for HIV disease","volume":"83","author":"Reust","year":"2011","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.coviro.2019.07.007_bib0500","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1093\/infdis\/jit043","article-title":"Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D Study","volume":"207","author":"Ryom","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2019.07.007_bib0505","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1128\/JVI.02717-15","article-title":"Antibody-dependent cellular cytotoxicity against reactivated HIV-1-infected cells","volume":"90","author":"Lee","year":"2016","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2019.07.007_bib0510","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1126\/science.1255512","article-title":"Immunologic strategies for HIV-1 remission and eradication","volume":"345","author":"Barouch","year":"2014","journal-title":"Science (80-)"},{"key":"10.1016\/j.coviro.2019.07.007_bib0515","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1089\/aid.1998.14.545","article-title":"Phase I study of a human monoclonal antibody directed against the CD4-binding site of HIV Type 1 glycoprotein 120","volume":"14","author":"Cavacini","year":"1998","journal-title":"AID Res Hum Retrovirus"},{"key":"10.1016\/j.coviro.2019.07.007_bib0520","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S0009-9236(96)90006-5","article-title":"Pharmacokinetics of F105, a human monoclonal antibody, in persons infected with human immunodeficiency virus type 1","volume":"59","author":"Wolfe","year":"1996","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.coviro.2019.07.007_bib0525","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/QAD.0000000000000570","article-title":"Passive transfer of neutralizing mAb KD-247 reduces plasma viral load in patients chronically infected with HIV-1","volume":"29","author":"Matsushita","year":"2015","journal-title":"Aids"},{"key":"10.1016\/j.coviro.2019.07.007_bib0530","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nature18929","article-title":"HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption","volume":"535","author":"Scheid","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2019.07.007_bib0535","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/cei.12692","article-title":"Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults","volume":"182","author":"Ledgerwood","year":"2015","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.coviro.2019.07.007_sbref0540","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nm.4268","article-title":"Antibody 10-1074 suppresses viremia in HIV-1-infected individuals","volume":"23","author":"Caskey","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.coviro.2019.07.007_bib0545","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/jac\/dkh428","article-title":"Passive immunization with the anti-HIV-1 human monoclonal antibody (hMAb) 4E10 and the hMAb combination 4E10\/2F5\/2G12","volume":"54","author":"Armbruster","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.coviro.2019.07.007_bib0550","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1128\/AAC.50.5.1773-1779.2006","article-title":"Long-term multiple-dose pharmacokinetics of human monoclonal antibodies (MAbs) against human immunodeficiency virus type 1 envelope gp120 (MAb 2G12) and gp41 (MAbs 4E10 and 2F5)","volume":"50","author":"Joos","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2019.07.007_bib0555","article-title":"Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail","volume":"9","author":"Julg","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coviro.2019.07.007_bib0560","doi-asserted-by":"crossref","first-page":"12669","DOI":"10.1128\/JVI.02213-14","article-title":"Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo","volume":"88","author":"Rudicell","year":"2014","journal-title":"J Virol"}],"container-title":["Current Opinion in Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625719300021?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625719300021?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T21:19:35Z","timestamp":1783631975000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879625719300021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":112,"alternative-id":["S1879625719300021"],"URL":"https:\/\/doi.org\/10.1016\/j.coviro.2019.07.007","relation":{},"ISSN":["1879-6257"],"issn-type":[{"value":"1879-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The potential of engineered antibodies for HIV-1 therapy and cure","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coviro.2019.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}